T
TG Therapeutics
TGTX
18.920
USD
-0.85
(-4.30%)
مفتوح الان
حجم التداول
57,776
الربح لكل سهم
0
العائد الربحي
0
P/E
35
حجم السوق
3,733,559,949
الأخبار
العنوان: TG Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.